Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why NovoCure Stock Dived by 13% This Week

TheMotleyFool

0 0

Why NovoCure Stock Dived by 13% This WeekPhoto, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

A series of C-suite changes negatively affected the share price of cancer-focused biotech NovoCure (NASDAQ: NVCR) across the holiday-shortened trading week. When the smoke cleared, the company's stock had eroded by slightly over 13% over the Tuesday to Friday stretch, according to data compiled by S&P Global Market Intelligence.

On Tuesday, NovoCure announced that long-serving CEO Asaf Danziger is stepping down, effective Jan. 1, 2025. He will be replaced by the biotech company's current CFO, Ashley Cordova.

Following the transition, Danziger will not be a stranger to NovoCure. He will serve as senior advisor to the company into early 2026, and continue to occupy a seat on its board of directors.

Source Fool.com

Like: 0

NVCR

Share